Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021 | 29 Nov 2021 |
| Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide | 22 Nov 2021 |
| Zealand Pharma increases its share capital as a consequence of exercise of employee warrants | 19 Nov 2021 |